Skip to main content

Development and Characterization of Doxorubicin Loaded Microparticles Against Experimental Visceral Leishmaniasis

Buy Article:

$107.14 + tax (Refund Policy)

Visceral leishmaniasis (VL) is the most severe of all the forms of leishmaniasis and usually lethal if untreated. The present work aimed to develop and characterize doxorubicin loaded mannan conjugated microparticles against experimental visceral leishmaniasis for selective and targeted delivery of doxorubicin to the macrophages of liver and spleen for the effective chemotherapy of VL. Macrophage targeting using doxorubicin loaded PLGA-microparticles would certainly improve the chemotherapy with reduced side effects against VL.


Document Type: Research Article

Publication date: January 1, 2011

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content